Ask me why this bill matters.

Congress.wiki Alpha

Color Theme:

About How Congress Works Support Us Roadmap Privacy Policy Terms of Service

This is not an official government website.

Copyright © 2026 PLEJ LC. All rights reserved.

Responsibility in Drug Advertising Act of 2025 (S-483) · Congress.wiki

Recorded Votes

Recorded roll calls only

0 recorded

No recorded votes yet

Text Versions

Introduced in Senate

February 6, 2025•4 pages

Related Legislation

What do you think?

Amendments

No Amendments

Sponsors (3)

House Votes

Vote Data Not Available

Senate Votes

Pending Committee

February 6, 2025

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Presidential Signature

Signature Data Not Available

AI Summary

United StatesSenate Bill 483S 483

Responsibility in Drug Advertising Act of 2025

Health

4 pages

senate

Prohibits most direct-to-consumer (DTC) advertising for newly approved prescription drugs and biologics during the first three years after FDA approval. The rule covers traditional media and social media, allows limited waivers, gives the Secretary authority to impose further safety-related prohibitions, and requires the Secretary to update implementing regulations within one year of enactment.

house

president

Introduced February 6, 2025 by Angus Stanley King · Last progress February 6, 2025

Connecticutrepresentative·Rosa L. Delauro

Responsibility in Drug Advertising Act of 2025

house

Bill

Health

senate

president

Updated 3/8/2026·Last progress February 7, 2025